AG announced its second major collaboration in recent weeks, this time with the Johnson & Johnson Innovation Center in California to identify new targets for
Alzheimer's disease drug discovery and development. Under the terms of the agreement, Janssen Pharmaceuticals, Inc., a member of the Johnson & Johnson
family of companies, and Evotec will work together to discover and develop novel treatments for Alzheimer's disease.
It can be difficult
at times, when discussing various aspects of the pharmaceutical and biotechnology industries, to remember that at the very base of the process is someone who
is hurting and afraid. Not a patient population from a clinical trial who act in a statistical manner, but a single individual with his or her own
experiences, biases and concerns.
When cell-sorting technology first arrived in the late 1970s, it
was used by academics and the medical research community to detect, count and characterize cells from the body and environment. As cell-sorting technology
evolved and improved, it also became more complex, unfortunately making it less accessible to many researchers. Fortunately, recent advances in
instrumentation have led to the development of much smaller, significantly less expensive and much easier-to-use cell-sorting devices, meaning that even
basic researchers can now access this useful technology.
2,832 pages: How do you measure, measure five years? This editorial column will be my last in Drug Discovery News, as in a few short
weeks, I will be stepping down from my post as chief editor of the news organization and entering a new chapter in my life. As I clean up my office and
prepare to pass the baton to Jeff Bouley, who will be your new chief editor in 2014, I am reflecting with great fondness some of the amazing people I have
met and the remarkable experiences I have had in the past five and a half years of leading our editorial team in the creation of these pages. Thus, as I exit
stage left, I will take inspiration from the song “Seasons of Love” from the hit musical “Rent” (which explains my headline and lead, if you’re not familiar
with it) and recall some of the memorable ways in which I will measure my tenure.